Nordicus Partners Corp - Quarter Report: 2019 September (Form 10-Q)

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE
	SECURITIES EXCHANGE ACT OF 1934
For the transition period from to

Commission File No. 0-28034
ADVANSOURCE BIOMATERIALS CORPORATION
(Name of small business issuer in its charter)
Delaware (State or other jurisdiction of incorporation or organization)			04-3186647 (I.R.S. Employer Identification No.)
229 Andover Street, Wilmington, Massachusetts (Address of principal executive offices)			01887 (Zip Code)
Issuer’s telephone number (424) 256-8560
Securities registered under Section 12(b) of the Exchange Act:
None Title of each class		None Name of each exchange on which registered

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.001 par value per share

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No q

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes xq No q

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

q Large Accelerated Filer		q Accelerated Filer
q Non-accelerated Filer		x Smaller reporting company
☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No x

As of November 13, 2019, 21,490,621 shares of the registrant’s Common Stock were outstanding.

ADVANSOURCE BIOMATERIALS CORPORATION

TABLE OF CONTENTS

		Page
PART I	FINANCIAL INFORMATION
Item 1	Unaudited Condensed Financial Statements
	Condensed Balance Sheets at September 30, 2019 (unaudited) and March 31, 2019	3
	Condensed Statements of Operations for the three and six months ended September 30, 2019 and 2018 (unaudited)	4
	Condensed Statements of Stockholders’ Deficit for the three and six months ended September 30, 2019 and 2018 (unaudited)	5
	Condensed Statement of Cash Flows for the six months ended September 30, 2019 and 2018 (unaudited)	6
	Notes to Condensed Financial Statements (unaudited)	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10
Item 3	Quantitative and Qualitative Disclosures About Market Risk	11
Item 4	Controls and Procedures	11
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	12
Item 1A.	Risk Factors	12
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	12
Item 3	Defaults Upon Senior Securities	12
Item 4	Mine Safety Disclosures	12
Item 5	Other Information	12
Item 6	Exhibits	13
	Signatures	14

ADVANSOURCE BIOMATERIALS CORPORATION

Balance Sheets

(In thousands, except per share and per share amounts)

	September 30, 2019	March 31, 2019
	(Unaudited)
ASSETS
Current assets:
Cash	`$456`	`$172`
Accounts receivable-trade, net of allowance of $5 as of September 30, 2019 and March 31, 2019	`254`	`483`
Accounts receivable-other	`174`	`185`
Inventories, net	`252`	`248`
Prepaid expenses and other current assets	`51`	`3`
Total current assets	`1,187`	`1,091`
Property, plant and equipment, net	`1,763`	`1,791`
Deferred financing costs, net	`49`	`52`
Other assets	`47`	`47`
Total assets	`$3,046`	`$2,981`
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable	`$447`	`$467`
Accrued expenses	`354`	`342`
Customer advance	`25`	`24`
Related party notes payable	`125`	`140`
Total current liabilities	`951`	`973`
Long-term liabilities:
Long-term financing obligation	`1,986`	`1,986`
Accrued interest on financing obligation	`160`	`168`
Total long-term liabilities	`2,146`	`2,154`
Total liabilities	`3,097`	`3,127`

Commitments and contingencies (See Note 14)	`-`	`-`

Stockholders' deficit:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of September 30, 2019 and March 31, 2019	`-`	`-`
Common stock; $.001 par value; 50,000,000 shares authorized; 21,567,313 shares issued; and 21,490,621 shares outstanding as of September 30, 2019 and March 31, 2019	`21`	`21`
Additional paid-in capital	`38,427`	`38,427`
Accumulated deficit	`(38,469)`	`(38,564)`
Treasury stock, 76,692 shares at cost as of September 30, 2019 and March 31, 2019	`(30)`	`(30)`
Total stockholders' deficit	`(51)`	`(146)`
Total liabilities and stockholders' deficit	`$3,046`	`$2,981`

The accompanying notes are an integral part of these unaudited condensed financial statements.

ADVANSOURCE BIOMATERIALS CORPORATION

Statements of Operations

(Unaudited – In thousands, except per share amounts)

	For the Three Months Ended September 30, 2019	For the Three Months Ended September 30, 2018	For the Six Months Ended September 30, 2019	For the Six Months Ended September 30, 2018

Revenues:
Product sales	`$514`	`$580`	`$1,175`	`$956`
License and royalty fees	`249`	`214`	`452`	`428`
Total revenues	`763`	`794`	`1,627`	`1,384`
Cost of sales	`192`	`239`	`447`	`412`
Gross profit	`571`	`555`	`1,180`	`972`
Operating expenses:
Research, development and regulatory	`79`	`87`	`177`	`176`
Selling, general and administrative	`340`	`349`	`674`	`674`
Total operating expenses	`419`	`436`	`851`	`850`
Income from operations	`152`	`119`	`329`	`122`
Interest expense	`(140)`	`(94)`	`(234)`	`(188)`
Net income (loss) before provision for income taxes	`12`	`25`	`95`	`(66)`
Provision for income taxes	`-`	`-`	`-`	`-`
Net income (loss)	`$12`	`$25`	`$95`	`$(66)`

Net income (loss) per common share:
Basic	`$0.00`	`$0.00`	`$0.00`	`$(0.00)`
Diluted	`$0.00`	`$0.00`	`$0.00`	`$(0.00)`

Shares used in computing net income (loss) per common share:
Basic	`21,491`	`21,491`	`21,491`	`21,491`
Diluted	`25,824`	`23,468`	`25,630`	`21,491`

The accompanying notes are an integral part of these unaudited condensed financial statements.

ADVANSOURCE BIOMATERIALS CORPORATION

Statement of Stockholders’ Deficit

(Unaudited – In thousands)

Preferred Stock

Common Stock

Shares

Amount

Shares

Amount

Additional Paid-in Capital

Accumulated Deficit

Treasury Stock

Total Stockholders' Deficit

Balance at March 31, 2018

-

$-

21,491

$21

$38,404

$(38,898)

$(30)

$(503)

Net loss

(91)

Balance at June 30, 2018

-

21,491

21

38,404

$(38,989)

$(30)

$(594)

Stock-based compensation

19

Net income

25

Balance at September 30, 2018

-

$-

21,491

$21

$38,423

$(38,964)

$(30)

$(550)

Balance at March 31, 2019

-

$-

21,491

$21

$38,427

$(38,564)

$(30)

$(146)

Net income

83

Balance at June 30, 2019

-

21,491

21

38,427

(38,481)

(30)

(63)

Net income

12

Balance at September 30, 2019

-

$-

21,491

$21

$38,427

$(38,469)

$(30)

$(51)

The accompanying notes are an integral part of these unaudited condensed financial statements.

ADVANSOURCE BIOMATERIALS CORPORATION

Statements of Cash Flows

(Unaudited – In thousands)

	For the Six Months Ended September 30, 2019	For the Six Months Ended September 30, 2018
Cash flows from operating activities:
Net income (loss)	`$95`	`$(66)`
Adjustments to reconcile net income (loss) to net cash flows provided by operating activities:
Depreciation	`28`	`29`
Amortization of deferred financing costs	`3`	`3`
Stock-based compensation	`-`	`19`
Changes in assets and liabilities:
Accounts receivable-trade	`229`	`(94)`
Accounts receivable-other	`11`	`187`
Inventories	`(4)`	`(3)`
Prepaid expenses and other current assets	`(48)`	`2`
Accounts payable	`(20)`	`(9)`
Accrued expenses	`4`	`7`
Customer advance	`1`	`(52)`
Deferred revenue	`-`	`24`
Net cash flows provided by operating activities	`299`	`47`
Cash flows from investing activities:
Purchase of equipment	`-`	`(24)`
Net cash flows used in investing activities	`-`	`(24)`
Cash flows from financing activities:
Repayment of related party notes payable	`(15)`	`-`
Net cash flows used in financing activities	`(15)`	`-`
Net change in cash	`284`	`23`
Cash at beginning of period	`172`	`120`
Cash at end of period	`$456`	`$143`

Supplemental disclosure of cash flow information:
Income taxes paid	`$-`	`$-`
Interest paid	`$175`	`$187`

The accompanying notes are an integral part of these unaudited condensed financial statements.

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

1.Business Description

AdvanSource Biomaterials Corporation develops advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. Our business model leverages our proprietary materials science technology and manufacturing expertise in order to expand product sales and royalty and license fee income.

Our technology, notably products such as ChronoFlex®, HydroMed™, and HydroThane™, which have been developed to overcome a wide range of design and functional challenges, such as the need for dimensional stability, ease of manufacture and demanding physical properties to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion. Our new product extensions customize proprietary polymers for specific customer applications in a wide range of device categories.

Our corporate, development and manufacturing operations are located in our leased facility in Wilmington, Massachusetts.

2.Interim Financial Statements and Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which we consider necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three and six months ended September 30, 2019 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The information contained in this quarterly report on Form 10-Q should be read in conjunction with our audited financial statements included in our annual report on Form 10-K, as of and for the year ended March 31, 2019 as filed with the Securities and Exchange Commission (the “SEC”).

Additionally, the accompanying unaudited financial statements have been prepared on a going concern basis which implies we will continue to meet our obligations for the next twelve months as of the date these financial statements are issued and contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the six months ended September 30, 2019, we recognized net income of approximately $95,000, had positive net cash flows of approximately $299,000 from operating activities and had a working capital surplus of approximately $236,000. Management believes that substantial doubt of our ability to meet our obligations for the next twelve months from the date these financial statements were first made available has been alleviated due to, but not limited to, i) continued growth of product sales from our current customer base and new customers; and ii) stable to increasing license fees and royalties pursuant to long-term contracts and arrangements. However, management cannot provide any assurances that we will be successful in accomplishing any of our plans. Management also cannot provide any assurance that unforeseen circumstances that could occur at any time within the next twelve months or thereafter will not increase the need for us to raise additional capital on an immediate basis. However, based upon our evaluation, management believes that we are a going concern.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments, which are evaluated on an ongoing basis, and that affect the amounts reported in our unaudited condensed financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to revenue recognition, allowance for doubtful accounts, inventory reserves, useful lives and valuation of property and equipment.

Our significant accounting policies are described in Note 3 to the audited financial statements as of March 31, 2019 which are included in our Annual Report on Form 10-K as filed with the SEC on August 23, 2019.

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

Revenue Recognition

We adopted the Accounting Standard Codification (“ASC”) 606, “Revenue from Contracts with Customers” as of April 1, 2018, using the modified retrospective method, and concluded that, consistent with prior reporting, we have two separate revenue streams: (i) product sales, and (ii) royalty and licensing revenues. Results for reporting periods after April 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with legacy accounting guidance under ASC 605, “Revenue Recognition.” The adoption of ASC 606 had no impact upon adoption, to our net income for the six months ended September 30, 2019.

ASC 606 defines a five-step process to recognize revenues at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. ASC 606 defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that an order to purchase product is agreed upon regardless of whether or not there is a written contract or when a contract is entered into for licensing and royalties.

We have two separate and distinct performance obligations offered to our customers: a product sales performance obligation and a licensing and royalty performance obligation. These performance obligations are related to separate revenue streams and at no point are they combined into a single transaction.

We generate the majority of our revenue from product sales, and to a lesser extent from fees generated from licensing and royalty arrangements primarily with two customers. Our revenue related to product sales is recognized upon shipment, provided that a purchase order has been received or a contract has been executed, there are no uncertainties regarding customer acceptance, the sales price is fixed or determinable and collection is deemed reasonably assured. If uncertainties regarding customer acceptance exist, we recognize revenues when those uncertainties are resolved and title has been transferred to the customer. Amounts collected or billed prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Our revenue related to licensing and royalty arrangements is recognized in accordance with the terms of the arrangements which typically provide for quarterly payment of exclusivity fees and royalties earned on the sale of customer products on a quarterly basis.

3.Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on our accounting and reporting. We believe that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on our accounting or reporting or that such impact will not be material to our financial position, results of operations and cash flows when implemented.

Recent accounting pronouncements are included in Note 3 to the financial statements included in Item 8 of our annual report on Form 10-K as of March 31, 2019.

4.Related Party Transactions

On April 26, 2016, we entered into Promissory Notes in the aggregate principal amount of $50,000 (the “Notes”) with Khristine Carroll, our Executive VP of Commercial Operations and an affiliate of Michael Adams, our Chief Executive Officer (the “Affiliate”) (collectively, the “Investors”). The Notes were initially due on May 25, 2016 and are currently being extended for consecutive monthly periods as mutually agreed upon by the parties and provided for by the terms of the Notes. The Notes bear interest at the rate of 10% per annum and all principal and accrued interest, if any, is due on demand.

During the three months ended September 30, 2019 and 2018, we repaid $0 and $0 of principal to Ms. Carroll. During the six months ended September 30, 2019 and 2018, we repaid $15,000 and $5,000 of principal to Ms. Carroll. As of September 30, 2019 and March 31, 2019, the aggregate principal balance outstanding on Ms. Carroll’s note was $0 and $15,000, respectively. As of September 30, 2019 and March 31, 2019, the aggregate principal balance outstanding on the Affiliate’s note was $25,000 and $25,000, respectively.

During the three months ended September 30, 2019 and 2018, we recorded interest expense of approximately $1,000 and $1,000, respectively, on the Notes. During the six months ended September 30, 2019 and 2018, we recorded interest expense of approximately $2,000 and $2,000, respectively, on the Notes. As of September 30, 2019 and March 31, 2019, there was no accrued interest outstanding on the Notes.

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

On December 5, 2016, we entered into an additional Promissory Note in the principal amount of $100,000 (the “Second Note”) with the Affiliate. The Second Note bears interest at the rate of 12% per annum, provides for a $3,000 commitment fee, which fee was paid in February 2017. Additionally, all principal and accrued interest, if any, which is due on demand, has been extended for consecutive month-to-month periods as mutually agreed to by the parties. As of September 30, 2019 and March 31, 2019, the principal balance outstanding was $100,000 and $100,000, respectively. During the three months ended September 30, 2019 and 2018 we recorded interest expense of approximately $3,000 and $3,000, respectively, on the Second Note. During the six months ended September 30, 2019 and 2018 we recorded interest expense of approximately $6,000 and $6,000, respectively, on the Second Note. As of September 30, 2019 and March 31, 2019, there was no accrued interest outstanding on the Second Note.

5.Inventories

Inventories, net of allowance for obsolete and excess inventory, are stated at the lower of cost (first in, first out) or market and consist of the following:

(in thousands)	September 30, 2019	March 31, 2019

Raw materials	`$135`	`$136`
Work in progress	`45`	`66`
Finished goods	`153`	`127`
	`333`	`329`
Less: allowance for obsolete and excess inventory	`(81)`	`(81)`
Total inventories, net	`$252`	`$248`

6.Property. Plant and Equipment

Property, plant and equipment consist of the following:

(in thousands)	September 30, 2019	March 31, 2019

Land	`$500`	`$500`
Building	`2,705`	`2,705`
Machinery, equipment and tooling	`1,248`	`1,248`
Furniture, fixtures and office equipment	`285`	`285`
Office equipment under capital lease	`13`	`13`
	`4,751`	`4,751`
Less: accumulated depreciation	`(2,988)`	`(2,960)`
Property, plant and equipment, net	`$1,763`	`$1,791`

Depreciation expense for the three months ended September 30, 2019 and 2018 was approximately $14,000 and $15,000, respectively. Depreciation expense for the six months ended September 30, 2019 and 2018 was approximately $28,000 and $29,000, respectively.

7.Income Per Share

Basic income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted income per common share are based upon the weighted-average common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method. In addition, the numerator is adjusted for any changes in income that would result from the assumed conversion of potential shares. Potentially dilutive shares, which were included in the diluted income per share

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

calculations for the three and six months ended September 30, 2019 were 4,333,209 shares and 4,139,568 shares. Potentially dilutive shares, which were included in the diluted income per share calculations for the three months ended September 30, 2018 were 1,977,688 shares. Potentially dilutive shares, which were excluded from the diluted income per share calculations because the effect would be antidilutive or the options exercise prices were greater than the average market price of the common shares, were 4,436,041 shares and 4,629,682 shares for the three and six months ended September 30, 2019. Potentially dilutive shares, which were excluded from the diluted income per share calculations because the effect would be antidilutive or the options exercise prices were greater than the average market price of the common shares, were 1,142,500 shares and 8,969,250 shares for the three and six months ended September 30, 2018.

8.Income Taxes

We are required to file federal and state income tax returns in the United States. The preparation of these tax returns requires us to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by us. In consultation with our tax advisors, we base our tax returns on interpretations that are believed to be reasonable under the circumstances. The tax returns, however, are subject to routine reviews by the various federal and state taxing authorities in the jurisdictions in which we file tax returns. As part of these reviews, a taxing authority may disagree with respect to the income tax positions taken by us (“uncertain tax positions”) and, therefore, may require us to pay additional taxes. As required under applicable accounting rules, we accrue an amount for our estimate of additional income tax liability, including interest and penalties, which we could incur as a result of the ultimate or effective resolution of the uncertain tax positions. We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

We had no income tax credits for the three and six months ended September 30, 2019 and 2018. The effective tax rates for the three and six months ended September 30, 2019 was 21.0%. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a federal corporate tax rate decrease from 35% to 21% for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of foreign earnings. We have estimated our provision for income taxes in accordance with the Tax Act and guidance available as of the date of this filing but have kept the full valuation allowance.

On December 22, 2017, Staff Accounting Bulletin No. 118 ("SAB 118") was issued to address the application of US GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The deferred tax expense recorded in connection with the remeasurement of deferred tax assets is a provisional amount and a reasonable estimate at December 31, 2017 based upon the best information currently available. The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act. Any subsequent adjustment to these amounts will be recorded to current tax expense in the quarter of 2018 when the analysis is complete. The accounting is expected to be complete when the 2018 corporate return is filed in 2019.

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

9.Promissory Notes

10.Long-Term Financing Obligation

On December 22, 2011, we entered into an agreement with an independent third-party under which we sold and leased back our land and building generating gross proceeds of $2,000,000. Pursuant to a lease agreement, the initial minimum lease term is 15 years. At the end of the initial minimum lease term, we have the option to renew the lease for three periods of five years each. In addition, we provided, as collateral, a security interest in all furnishings, fixtures and equipment owned and used by us, having a net book value of approximately $0 as of September 30, 2019. For accounting purposes, the provision of such collateral constitutes continuing involvement with the associated property. Due to this continuing involvement, this sale-leaseback transaction is accounted for under the financing method, rather than as a completed sale. Under the financing method, we include the sales proceeds received as a financing obligation. As of September 30, 2019 and March 31, 2019, the total financing obligation was $1,986,000, respectively, and accrued interest on financing obligation was approximately $160,000 and $168,000, respectively. Through December 2018, interest on the financing obligation exceeded the minimum lease payments, accordingly the principal remains constant through that date. After December 2018, the minimum lease payment will exceed interest and principal will be reduced by the excess of minimum lease payment over interest. The building, building improvements and land remain on the condensed balance sheet and the building and building improvements will continue to be depreciated over their remaining useful lives. Payments made under the lease are applied as payments of imputed interest and deemed principal on the underlying financing obligation.

11.Stockholders’ Deficit

Common Stock Options and Warrants

On July 22, 2015, we engaged the services of a financial and strategic advisor whose services include, but are not limited to, financial advice, strategic advice and investment banking services. In connection with this engagement, we agreed to compensate the investment bankers approximately $4,000 per quarter for a one-year period and we issued them a warrant to purchase 830,500 shares of our common stock at an exercise price of $0.03 per share, the approximate fair value of our common stock on the date of the engagement. The warrant is exercisable at any time until July 21, 2025. The warrant was valued at approximately $28,000 using the Black-Scholes model and treated as

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

permanent equity.

There were no exercises of options or warrants by employees or consultants during the three and six months ended September 30, 2019 and 2018.

12.Stock-Based Compensation

In October 2003, our shareholders approved the AdvanSource 2003 Stock Option Plan (the “2003 Plan”), which authorizes the issuance of 3,000,000 shares of common stock. Under the terms of the Plan, the exercise price of Incentive Stock Options issued under the Plan must be equal to the fair market value of the common stock at the date of grant. In the event that Non-Qualified Options are granted under the Plan, the exercise price may be less than the fair market value of the common stock at the time of the grant (but not less than par value). Total shares of common stock registered under the 2003 Plan are 7,000,000 shares. Normally, options granted expire ten years from the grant date.

Activity under the 2003 Plan for the six months ended September 30, 2019 is as follows:

	Number of Options	Weighted-Average Exercise Price per Share	Weighted-Average Remaining Contractual Term in Years	Aggregate Intrinsic Value (in thousands)
Options outstanding as of April 1, 2019	`1,788,750`	`$0.20`	`2.03`	`$20`
Granted	`-`
Exercised	`-`
Cancelled or forfeited	`(400,000)`
Options outstanding as of September 30, 2019	`1,388,750`	`$0.17`	`2.02`	`$77`
Options exercisable as of September 30, 2019	`1,388,750`	`$0.17`	`2.02`	`$77`
Options vested or expected to vest as of September 30, 2019	`1,388,750`	`$0.17`	`2.02`	`$77`

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on September 30, 2019 of $0.176 and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on September 30, 2019. There were no stock options exercised under the 2003 Plan for the three and months ended September 30, 2019 and 2018. As of September 30, 2019, there were no shares remaining to be granted under the 2003 Plan.

For the three and six months ended September 30, 2019 and 2018, we recorded no stock-based compensation expense for options pursuant to the 2003 Plan. As of September 30, 2019, we had no unrecognized compensation cost related to stock options.

On August 14, 2017, our board of directors approved and adopted the 2017 Non-Qualified Equity Incentive Plan (the “2017 Plan”), which authorized the grant of non-qualified stock options exercisable into a maximum of 7,000,000 shares of our common stock. Under the terms of the 2017 Plan, the exercise price of stock options issued under the 2017 Plan must be equal to the fair market value of the common stock at the date of grant. Options granted expire ten years from the grant date. From August 17, 2017 through December 13, 2018, the board of directors approved the grant of stock options to certain directors, employees and a consultant which were immediately vested and exercisable into a total of 6,550,000 shares of our common stock. There were no additional stock options granted pursuant to the 2017 Plan for the period subsequent to December 31, 2018. In determining the fair value of the 2017 Stock Options, we utilized the Black-Scholes pricing model utilizing the following assumptions:

ADVANSOURCE BIOMATERIALS CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

September 30, 2019

(UNAUDITED)

	August 17, 2017 Option Grants	August 16, 2018 Option Grants	December 13, 2018 Option Grants
Total shares granted	`5,600,000`	`750,000`	`200,000`
Option exercise price per share	`$0.06`	`$0.040`	`$0.060`
Grant date fair market value per share	`$0.06`	`$0.046`	`$0.059`
Expected term of option in years	`10.0`	`2.00`	`1.00`
Expected volatility	`100%`	`100%`	`100%`
Expected dividend rate	`0.00%`	`0.00%`	`0.00%`
Risk free interest rate	`1.00%`	`0.00%`	`2.69%`

13.Concentrations of Credit Risk and Major Customers

For the three months ended September 30, 2019 and 2018, three customers represented approximately 50% of our total revenues and three customers represented approximately 54% of our total revenues, respectively.

For the six months ended September 30, 2019 and 2018, three customers represented approximately 50% of our total revenues and three customers represented approximately 52% of our total revenues, respectively.

As of September 30, 2019, we had accounts receivable-trade of approximately $$140,000, or 55%, due from three customers. As of March 31, 2019, we had accounts receivable-trade of approximately $61,000, or 13%, due from one customer.

As of September 30, 2019 and March 31, 2019, we had approximately $174,000 due from two customers and $185,000 due from two customers, respectively, related to receivables on license fees and royalties. These amounts are classified as accounts receivable-other in our balance sheets.

14.Legal Proceedings

We are not the subject of any pending legal proceedings; and to the knowledge of management, no proceedings are presently contemplated against us by any federal, state or local governmental agency. Further, to the knowledge of management, no director or executive officer is party to any action in which any has an interest adverse to us.

15.Subsequent Events

We evaluated all events or transactions that occurred after the balance sheet date through the date when we filed these financial statements and we determined that we did not have any other material recognizable subsequent events.

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This quarterly report on Form 10-Q contains certain statements that are “forward-looking” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Litigation Reform Act”). These forward looking statements and other information are based on our beliefs as well as assumptions made by us using information currently available.

The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “will,” “should” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or using other similar expressions.

In accordance with the provisions of the Litigation Reform Act, we are making investors aware that such forward-looking statements, because they relate to future events, are by their very nature subject to many important factors that could cause actual results to differ materially from those contemplated by the forward-looking statements contained in this quarterly report on Form 10-Q. For example, we may encounter competitive, technological, financial and business challenges making it more difficult than expected to continue to develop and market our products; the market may not accept our existing and future products; we may not be able to retain our customers; we may be unable to retain existing key management personnel; and there may be other material adverse changes in our operations or business. Certain important factors affecting the forward-looking statements made herein also include, but are not limited to (i) continued downward pricing pressures in our targeted markets, (ii) the continued acquisition of our customers by certain of our competitors, and (iii) continued periods of net losses, which could require us to find additional sources of financing to fund operations, implement our financial and business strategies, meet anticipated capital expenditures and fund research and development costs. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and business developments, the impact of which may cause us to alter our marketing, capital expenditure or other budgets, which may in turn affect our financial position and results of operations. For all of these reasons, the reader is cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date hereof. We assume no responsibility to update any forward-looking statements as a result of new information, future events, or otherwise except as required by law. For further information, you are encouraged to review our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2019 and the risk factors discussed therein under Part I. Item 1A.

Overview

We develop advanced polymer materials which provide critical characteristics in the design and development of medical devices. Our biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. Our business model leverages our proprietary materials science technology and manufacturing expertise in order to expand our product sales and royalty and license fee income.

Our leading edge technology, notably products such as ChronoFlex®, HydroMed™, and HydroThane™, has been developed to overcome a wide range of design and functional challenges, from the need for dimensional stability, ease of manufacturability and demanding physical properties to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion. Our polymer product lines are compliant with measures applying to the processing of certain animal waste to protect against transmissible spongiform encephalopathies as set forth in European Council Decision 1999/534/EC. Our new product extensions allow us to customize our proprietary polymers for specific customer applications in a wide range of device categories.

Technology and Intellectual Property

Our unique materials science strengths are embodied in our family of proprietary polymers. We manufacture and sell our custom polymers under the trade names ChronoFilm, ChronoFlex, ChronoThane, ChronoPrene, ChronoSil, HydroThane, and PolyBlend. The ChronoFlex family of polymers has the potential to be marketed beyond our existing customer base. Our goal is to fulfill the market’s need for advanced materials science capabilities, thereby enabling customers to improve devices that utilize polymers. Our chemists continue to develop the ChronoFlex family of medical-grade polymers. Conventional polymers are susceptible to degradation resulting in catastrophic failure of long-term implantable devices such as pacemaker leads. ChronoFlex and ChronoThane polymers are designed to overcome such degradation and reduce the incidents of infections associated with invasive devices.

Key characteristics of our polymers are i) optional use as lubricious coatings for smooth insertion of a device into the body, ii) antimicrobial properties that are part of the polymer itself, and iii) mechanical properties, such as hardness and elasticity sufficient to meet engineering requirements. We believe our technology has wide application in increasing biocompatibility, drug delivery, infection control and expanding the utility of complex devices in the hospital and clinical environment.

We manufacture and sell our proprietary HydroThane polymers to medical device manufacturers that are evaluating HydroThane for use in their products. HydroThane is a thermoplastic, water-absorbing, polyurethane elastomer possessing properties which we believe make it well suited for the complex requirements of a variety of catheters. In addition to its physical properties, we believe HydroThane exhibits an inherent degree of bacterial resistance, clot resistance and biocompatibility. When hydrated, HydroThane has elastic properties similar to living tissue.

We also manufacture specialty hydrophilic polyurethanes that are primarily sold to customers as part of exclusive arrangements. Specifically, one customer is supplied tailored, patented hydrophilic polyurethanes in exchange for a multi-year, royalty-bearing exclusive supply contract which generates royalty income for the Company.

ChronoFilm is a registered trademark of PolyMedica. ChronoFlex is our registered trademark. ChronoThane, ChronoPrene, ChronoSil, HydroThane, and PolyBlend are our tradenames. CardioPass is our trademark.

We own or license four patents relating to our vascular graft manufacturing and polymer technology and products. While we believe our patents secure our exclusivity with respect to certain of our technologies, there can be no assurance that any patents issued would not afford us adequate protection against competitors which sell similar inventions or devices, nor can there be any assurance that our patents will not be infringed upon or designed around by others. However, we intend to vigorously enforce all patents issued to us.

In October 2009, we filed for a U.S. patent on ChronoSil, our silicone-urethane copolymer product, and methods for making ChronoSil. ChronoSil can have many physical properties which are usually associated with polyurethanes, but also the feel and characteristics of silicones.

In August 2010, the U.S. Patent and Trademark Office issued us a U.S. patent on our proprietary antimicrobial formulation for ChronoFlex. Current technology in the marketplace uses antibiotic drugs. The antimicrobial component of our polymers has been designed to be non-leaching as a result of the polymerization process.

In addition, PolyMedica has granted us an exclusive, perpetual, worldwide, royalty-free license for the use of one polyurethane patent and related technology in the field consisting of the development, manufacture and sale of implantable medical devices and biodurable polymer material to third parties for the use in medical applications (the “Implantable Device and Materials Field”). PolyMedica also owns, jointly with Thermedics, Inc., an unrelated company that manufactures medical grade polyurethane, the ChronoFlex polyurethane patents relating to the ChronoFlex technology. PolyMedica has granted us a non-exclusive, perpetual, worldwide, royalty-free sublicense of these patents for use in the Implantable Devices and Materials Field.

Critical Accounting Policies

Our critical accounting policies are summarized in Note 3 to our consolidated financial statements included in Item 8 of our annual report on Form 10-K for the fiscal year ended March 31, 2019. However, certain of our accounting policies require the application of significant judgment by our management, and such judgments are reflected in the amounts reported in our financial statements. In applying these policies, our management uses its judgment to determine the appropriate assumptions to be used in the determination of estimates. Those estimates are based on our historical experience, terms of existing contracts, our observance of market trends, information provided by our strategic partners and information available from other outside sources, as appropriate. Actual results may differ significantly from the estimates contained in our unaudited condensed financial statements. There have been no changes to our critical accounting policies during the fiscal quarter ended September 30, 2019.

Results of Operations

For the Three Months Ended September 30, 2019 vs September 30, 2018

Revenues

Total revenues for the three months ended September 30, 2019 were approximately $763,000 as compared with approximately $794,000 for the prior year period, a decrease of approximately $31,000, or 3.9%.

Product sales of our biomaterials for the three months ended September 30, 2019 were approximately $514,000 as compared with approximately $580,000 for the prior year period, a decrease of approximately $66,000, or 11.4%. The decrease is due to anticipated reductions in product shipments to certain key customers.

License and royalty fees for the three months ended September 30, 2019 were approximately $249,000 as compared with approximately $214,000 for the prior year period, an increase of approximately $35,000 or 16.4%. Our license and royalty fees remain relatively stable and consistent pursuant to the terms of the long-term contracts and arrangements with two of our significant customers. We have agreements to license our proprietary biomaterial technology to medical device manufacturers and develop biomaterials for incorporation into medical devices under development by our customers. Royalties are earned when these manufacturers sell medical devices which use our biomaterials.

Gross Profit

Gross profit on total revenues for the three months ended September 30, 2019 was approximately $571,000, or 74.8% of total revenues, compared with approximately $555,000, or 69.9% of total revenues, for the prior year period. Gross dollars and gross profit as a percentage of total revenues for the three months ended September 30, 2019 as compared to the prior year period increased primarily due to recognition of license fees from one customer upon receipt of payment which had previously been recorded ratable over the prior year period. The immediate recognition of the license fees from the one customer was a result of the adoption of ASC 606.

Gross profit on product sales for the three months ended September 30, 2019 was approximately $322,000, or 62.7% of product sales, compared with approximately $341,000, or 58.8% of product sales, for the prior year period. Gross profit dollars as a percentage of total revenues for the three months ended September 30, 2019 as compared to the prior year period decreased primarily due to decreased product sales. Gross profit as a percentage of total revenues for the three months ended September 30, 2019 as compared to the prior year period increased primarily due to improved yields and raw material costs.

Research, Development and Regulatory Expenses

Research and development expenses for the three months ended September 30, 2019 were approximately $79,000 as compared with approximately $87,000 for the prior year period, a decrease of approximately $8,000, or 9.2%. Research and development expense continue to remain relatively stable from period to period. Our research and development efforts are focused on developing new applications for our biomaterials. Research and development expenditures consist primarily of the salaries of full-time employees, research consultant fees and related expenses, and are expensed as incurred. Management believes its current research and development resources meet the needs of our customers and internal development needs.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended September 30, 2019 were approximately $340,000 as compared with approximately $349,000 for the prior year period, a decrease of approximately $9,000, or 2.6%. Selling, general and administrative expenses continue to remain relatively stable.

Interest Expense

Interest expense for the three months ended September 30, 2019 was approximately $140,000 as compared to approximately $94,000 for the comparable prior year period, an increase of $46,000 or 48.9%. Interest expense is composed primarily of (i) interest accrued in connection with the financing obligation of approximately $87,000 and $88,000 for the three months ended September 30, 2019 and 2018, respectively; and (ii) accrual of interest of approximately $46,000 on local regulatory obligations.

For the Six Months Ended September 30, 2019 vs September 30, 2018

Revenues

Total revenues for the six months ended September 30, 2019 were approximately $1,627,000 as compared with approximately $1,384,000 for the prior year period, an increase of approximately $243,000, or 17.6%.

Product sales of our biomaterials for the six months ended September 30, 2019 were approximately $1,175,000 as compared with approximately $956,000 for the prior year period, an increase of approximately $219,000, or 22.9%. The increase is due to continued demand from certain key existing customers and continued penetration of the market resulting in an expanding customer base.

License and royalty fees for the six months ended September 30, 2019 were approximately $452,000 as compared with approximately $428,000 for the prior year period, an increase of approximately $24,000 or 5.6%. Our license and royalty fees remain relatively stable and consistent pursuant to the terms of the long-term contracts and arrangements with two of our significant customers. We have agreements to license our proprietary biomaterial technology to medical device manufacturers and develop biomaterials for incorporation into medical devices under development by our customers. Royalties are earned when these manufacturers sell medical devices which use our biomaterials.

Gross Profit

Gross profit on total revenues for the six months ended September 30, 2019 was approximately $1,180,000, or 72.5% of total revenues, compared with approximately $972,000, or 70.2% of total revenues, for the prior year period. Gross dollars and gross profit as a percentage of total revenues for the six months ended September 30, 2019 as compared to the prior year period increased primarily due to (i) increase in product sales and (ii) recognition of license fees from one customer upon receipt of payment which had previously been recorded ratable over the prior year period. The immediate recognition of the license fees from the one customer was a result of the adoption of ASC 606.

Gross profit on product sales for the six months ended September 30, 2019 was approximately $728,000, or 62.0% of product sales, compared with approximately $544,000, or 56.9% of product sales, for the prior year period. Gross profit dollars and gross profit as a percentage of total revenues for the six months ended September 30, 2019 as compared to the prior year period increased primarily due to increased product sales.

Research, Development and Regulatory Expenses

Research and development expenses for the six months ended September 30, 2019 were approximately $177,000 as compared with approximately $176,000 for the prior year period, an increase of approximately $1,000, or less than 1.0%. Research and development expense continue to remain relatively stable from period to period. Our research and development efforts are focused on developing new applications for our biomaterials. Research and development expenditures consist primarily of the salaries of full-time employees, research consultant fees and related expenses, and are expensed as incurred. Management believes its current research and development resources meet the needs of our customers and internal development needs.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the six months ended September 30, 2019 were approximately $674,000 as compared with approximately $674,000 for the prior year period. Selling, general and administrative expenses continue to remain relatively stable.

Interest Expense

Interest expense for the six months ended September 30, 2019 was approximately $234,000 as compared to approximately $188,000 for the comparable prior year period, an increase of $46,000 or 24.5%. Interest expense is composed primarily of (i) interest accrued in connection with the financing obligation of approximately $175,000 and $176,000 for the six months ended September 30, 2019 and 2018, respectively; and (ii) accrual of interest of approximately $46,000 on local regulatory obligations.

Liquidity and Capital Resources

As of September 30, 2019, we had cash of approximately $456,000 as compared to a cash balance of approximately $172,000 as of March 31, 2019.

During the six months ended September 30, 2019, we had net cash of approximately $299,000 provided by operating activities as compared with net cash of approximately $47,000 provided by operating activities for the prior year period. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs, material and overhead costs used in production, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from customers on the sale of polymer products, customer advances and fees earned on license, royalty and development agreements. Our net cash provided by operating activities during the six months ended September 30, 2019 increased primarily as a result of: (i) net income of $95,000; and (ii) decrease of accounts receivable – trade of $229,000.

During the six months ended September 30, 2019, we used no cash for investing activities as compared to the use of approximately $24,000 for investing activities in connection with the purchase of production equipment in the comparable prior year period.

During the six months ended September 30, 2019, we used cash of $15,000 for financing activities in connection with the repayment of a related party note.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the six months ended September 30, 2019, we recognized net income of approximately $95,000, had positive net cash flows of approximately $299,000 from operations and had a working capital surplus of approximately $236,000. Management believes that substantial doubt of our ability to meet our obligations for the next twelve months from the date these financial statements were first made available has been alleviated due to, but not limited to, i) continued growth of product sales from our current customer base and new customers; and ii) stable to increasing license fees and royalties pursuant to long-term contracts and arrangements. However, management cannot provide any assurances that we will be successful in accomplishing any of our plans. Management also cannot provide any assurance that unforeseen circumstances that could occur at any time within the next twelve months or thereafter will not increase the need for us to raise additional capital on an immediate basis. However, based upon our evaluation, management believes that we are a going concern.

Any potential future sale of equity or debt securities may result in dilution to our stockholders, and we cannot be certain that additional public or private financing will be available in amounts or on terms acceptable to us, or at all. If we are required to raise additional financing, but are unable to obtain such financing, we may be required to delay, reduce the scope of, or eliminate one or more aspects of our operations or business development activities.

Commitments

We do not have any long-term commitments at September 30, 2019.

Off-Balance Sheet Arrangements

As of September 30, 2019, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

Item 3.Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4.Controls and Procedures

The certificates of our principal executive officer and principal financial and accounting officer attached as Exhibits 31.1 and 31.2 to this Quarterly Report on Form 10-Q include, in paragraph 4 of such certifications, information concerning our disclosure controls and procedures, and internal control over financial reporting. Such certifications should be read in conjunction with the information contained in this Item 4 for a more complete understanding of the matters covered by such certifications.

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its chief executive officer and chief financial officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer concluded that our disclosure controls and procedures as of September 30, 2019 were not effective at the reasonable assurance level due to limited resources in the finance and accounting functions. We intend to take appropriate and reasonable steps to make improvements to

remediate these deficiencies.

Changes in Internal Control Over Financial Reporting

There were no changes to the Company’s internal control over financial reporting during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II.OTHER INFORMATION

Item 1.Legal Proceedings

Item 1A.Risk Factors

Not applicable.

Item 2.Unregistered Sales of Equity Securities

None.

Item 3.Defaults Upon Senior Securities

None.

Item 4.Mine Safety Disclosures

Not applicable.

Item 5.Other Information

None.

Item 6.Exhibits

Exhibit No.		Description
31.1		Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of the Principal Financial and Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of the Chief Executive Officer Pursuant to 18 U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxomony Extension Calculation Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ADVANSOURCE BIOMATERIALS CORPORATION
	By:	/s/ Michael F. Adams
		Michael F. Adams Chief Executive Officer and President (Principal Executive, Financial and Accounting Officer)

Dated: November 13, 2019